Avalyn Pharma Inc. officer Melissa Rhodes filed a Form 144 notice on November 17, 2026, disclosing a proposed sale of 13,300 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services.

Key Highlights

  • Proposed seller: Melissa Rhodes, an officer of Avalyn Pharma Inc.
  • Shares proposed for sale: 13,300 shares of common stock, with an aggregate market value of $395,808.00
  • Acquisition method: The shares were acquired on November 17, 2026, through the exercise of stock options granted by the issuer, with payment made in cash
  • Approximate sale date: November 17, 2026, through NASDAQ via Morgan Stanley Smith Barney LLC Executive Financial Services
  • Shares outstanding: 44,521,494 shares of common stock outstanding at the time of the filing
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 plan adoption date of July 30, 2026
  • Prior sales: No securities of the issuer were sold by Rhodes during the past three months, according to the filing

Avalyn Pharma Officer Discloses Proposed Stock Sale Under Rule 144

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Melissa Rhodes, identified as an officer of Avalyn Pharma Inc. (NASDAQ:AVLN), proposed to sell 13,300 shares of the company's common stock. The filing lists an aggregate market value of $395,808.00 for the proposed sale. The broker named to execute the transaction is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

The filing discloses that the 13,300 shares to be sold were acquired on November 17, 2026, through the exercise of stock options issued by Avalyn Pharma Inc., with the acquisition payment made in cash on the same date. The filing notes that the proposed sale is linked to a Rule 10b5-1 trading plan adopted on July 30, 2026. As of the filing date, Avalyn Pharma had approximately 44,521,494 shares of common stock outstanding, according to the disclosure.

The filing states that Rhodes reported no sales of Avalyn Pharma securities during the three months preceding the notice. By signing the Form 144, Rhodes represented, as of the plan adoption date, that she was not in possession of any material adverse information regarding the current and prospective operations of Avalyn Pharma that had not been publicly disclosed, as stated in the filing's attestation language.

What Was Disclosed

Avalyn Pharma officer Melissa Rhodes filed a Form 144 notice proposing the sale of 13,300 shares of common stock, acquired through stock option exercise, with an aggregate market value of $395,808.00, under a Rule 10b5-1 plan adopted July 30, 2026.